{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T17:06:14Z","timestamp":1778519174795,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010014","name":"Six Talent Peaks Project in Jiangsu Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010014","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.lfs.2022.120439","type":"journal-article","created":{"date-parts":[[2022,2,27]],"date-time":"2022-02-27T17:13:38Z","timestamp":1645982018000},"page":"120439","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Docetaxel and 5-FU enhanced the inhibitory effects of apatinib and ramucirumab on growth and migration of gastric cancer"],"prefix":"10.1016","volume":"296","author":[{"given":"Jia-Qi","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruo-Yue","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong-Yong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Zong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Fang","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin-En","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.lfs.2022.120439_bb0005","first-page":"115","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J. Clin."},{"issue":"10","key":"10.1016\/j.lfs.2022.120439_bb0010","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.6004\/jnccn.2016.0137","article-title":"Gastric cancer, version 3.2016, NCCN clinical practice guidelines in oncology","volume":"14","author":"Ajani","year":"2016","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"1","key":"10.1016\/j.lfs.2022.120439_bb0015","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1186\/s12885-021-08459-3","article-title":"Short-term survival and safety of apatinib combined with oxaliplatin and S-1 in the conversion therapy of unresectable gastric cancer","volume":"21","author":"Ye","year":"2021","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.lfs.2022.120439_bb0020","doi-asserted-by":"crossref","DOI":"10.1186\/s40164-019-0149-6","article-title":"Targeted and novel therapy in advanced gastric cancer","volume":"8","author":"Selim","year":"2019","journal-title":"Exp. Hematol. Oncol."},{"issue":"9911","key":"10.1016\/j.lfs.2022.120439_bb0025","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Charles","year":"2014","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.lfs.2022.120439_bb0030","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol."},{"issue":"13","key":"10.1016\/j.lfs.2022.120439_bb0035","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1200\/JCO.2015.63.5995","article-title":"Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction","volume":"34","author":"Li","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lfs.2022.120439_bb0040","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.2147\/DDDT.S170678","article-title":"Efficacy and safety of apatinib combined with chemotherapy for the treatment of advanced gastric cancer in the Chinese population: a systematic review and meta-analysis","volume":"12","author":"Cheng","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.lfs.2022.120439_bb0045","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.2147\/OTT.S193801","article-title":"Concurrent apatinib and docetaxel vs apatinib monotherapy as third- or subsequent-line therapy for advanced gastric adenocarcinoma: a retrospective study","volume":"12","author":"Lin","year":"2019","journal-title":"OncoTargets Ther."},{"issue":"5","key":"10.1016\/j.lfs.2022.120439_bb0050","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1158\/1078-0432.CCR-14-2921","article-title":"Zebrafish: a new companion for translational research in oncology","volume":"21","author":"Barriuso","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.lfs.2022.120439_bb0055","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3390\/cancers9110146","article-title":"Advances in precision medicine: tailoring individualized therapies","volume":"9","author":"Matchett","year":"2017","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.lfs.2022.120439_bb0060","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/nm.3954","article-title":"High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response","volume":"21","author":"Gao","year":"2015","journal-title":"Nat. Med."},{"issue":"39","key":"10.1016\/j.lfs.2022.120439_bb0065","doi-asserted-by":"crossref","first-page":"8234","DOI":"10.1073\/pnas.1618389114","article-title":"Single-cell functional and chemosensitive profiling of combinatorial colorectal therapy in zebrafish xenografts","volume":"114","author":"Fior","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.lfs.2022.120439_bb0070","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/1471-2407-9-128","article-title":"Metastatic behaviour of primary human tumours in a zebrafish xenotransplantation model","volume":"9","author":"Marques","year":"2009","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.lfs.2022.120439_bb0075","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.cell.2019.04.004","article-title":"Visualizing engrafted human cancer and therapy responses in immunodeficient zebrafish","volume":"177","author":"Yan","year":"2019","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.lfs.2022.120439_bb0080","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s12020-016-1048-9","article-title":"Patient-derived xenograft in zebrafish embryos: a new platform for translational research in neuroendocrine tumors","volume":"57","author":"Gaudenzi","year":"2017","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.lfs.2022.120439_bb0085","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3324\/haematol.2014.110742","article-title":"Focused chemical genomics using zebrafish xenotransplantation as a pre-clinical therapeutic platform for T-cell acute lymphoblastic leukemia","volume":"100","author":"Bentley","year":"2015","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.lfs.2022.120439_bb0090","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s13046-017-0631-0","article-title":"Patient-derived xenograft in zebrafish embryos: a new platform for translational research in gastric cancer","volume":"36","author":"Wu","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"23","key":"10.1016\/j.lfs.2022.120439_bb0095","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.2217\/fon-2019-0243","article-title":"Ramucirumab and paclitaxel in patients with gastric cancer and prior trastuzumab: subgroup analysis from RAINBOW study","volume":"15","author":"Vita","year":"2019","journal-title":"Future Oncol."},{"issue":"6","key":"10.1016\/j.lfs.2022.120439_bb0100","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1007\/s10120-019-00958-4","article-title":"A phase I\/II study of poziotinib combined with paclitaxel and trastuzumab in patients with HER2-positive advanced gastric cancer","volume":"22","author":"Kim","year":"2019","journal-title":"Gastric Cancer"},{"issue":"1","key":"10.1016\/j.lfs.2022.120439_bb0105","first-page":"106","article-title":"Safety, pharmacokinetic, and clinical activity profiles of ramucirumab in combination with three platinum\/fluoropyrimidine doublets in Japanese patients with chemotherapy-na\u00efve metastatic gastric\/gastroesophageal junction cancer","volume":"21","author":"Kohei","year":"2017","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.lfs.2022.120439_bb0110","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.2147\/OTT.S159935","article-title":"The synergistic effects of apatinib combined with cytotoxic chemotherapeutic agents on gastric cancer cells and in a fluorescence imaging gastric cancer xenograft model","volume":"11","author":"Feng","year":"2018","journal-title":"Oncotargets Ther."},{"issue":"7","key":"10.1016\/j.lfs.2022.120439_bb0115","article-title":"Autocrine VEGF signaling promotes cell proliferation through a PLC-dependent pathway and modulates apatinib treatment efficacy in gastric cancer","volume":"8","author":"Yi","year":"2017","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.lfs.2022.120439_bb0120","doi-asserted-by":"crossref","first-page":"11990","DOI":"10.18632\/oncotarget.14467","article-title":"Autocrine VEGF signaling promotes cell proliferation through a PLC-dependent pathway and modulates apatinib treatment efficacy in gastric cancer","volume":"8","author":"Lin","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.lfs.2022.120439_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MOG.0000000000000577","article-title":"Advances in the treatment of gastric cancer: 2019","volume":"35","author":"Ilson","year":"2019","journal-title":"Curr. Opin. Gastroenterol."},{"issue":"8","key":"10.1016\/j.lfs.2022.120439_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CAD.0000000000000380","article-title":"Apatinib in metastatic gastric cancer: can paclitaxel make the difference?","volume":"27","author":"Roviello","year":"2016","journal-title":"Anti-Cancer Drugs"},{"issue":"7","key":"10.1016\/j.lfs.2022.120439_bb0135","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/apm.12201","article-title":"Metronomic chemotherapy and anti-angiogenesis: can upgraded pre-clinical assays improve clinical trials aimed at controlling tumor growth?","volume":"122","author":"Norrby and Klas","year":"2014","journal-title":"Apmis Acta Pathologica Microbiologica Et Immunologica Scandinavica"},{"key":"10.1016\/j.lfs.2022.120439_bb0140","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.2147\/CMAR.S196372","article-title":"Apatinib enhances chemosensitivity of gastric cancer to paclitaxel and 5-fluorouracil","volume":"11","author":"Xu","year":"2019","journal-title":"Cancer Manag. Res."},{"issue":"3","key":"10.1016\/j.lfs.2022.120439_bb0145","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"issue":"6","key":"10.1016\/j.lfs.2022.120439_bb0150","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3390\/cancers11060787","article-title":"Ramucirumab and GSK1838705A enhance the inhibitory effects of low concentration sorafenib and regorafenib combination on HCC cell growth and motility","volume":"11","author":"D'Alessandro","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lfs.2022.120439_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117402","article-title":"A systematical comparison of anti-angiogenesis and anti-cancer efficacy of ramucirumab, apatinib, regorafenib and cabozantinib in zebrafish model","volume":"247","author":"Wu","year":"2020","journal-title":"Life Sci."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320522001394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320522001394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T20:57:40Z","timestamp":1758401860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320522001394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":31,"alternative-id":["S0024320522001394"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2022.120439","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Docetaxel and 5-FU enhanced the inhibitory effects of apatinib and ramucirumab on growth and migration of gastric cancer","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2022.120439","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"120439"}}